Abstract：[Objective]To explore the effect of early use of rosuvastatin on blood lipids and inflammatory factors high sensitive C‐reactive protein(hs‐CRP) and interleukin‐6(IL‐6) in patients with acute coronary syndrome(ACS) .[Meth‐ods]A total of 54 patients confirmed as ACS by clinical diagnosis in our hospital were chosen and randomly divided into routine treatment group(group A ,n=26) and rosuvastatin treatment group(group B ,n =28) by using randomization case control method .Other 20 concurrent healthy subjects were chosen as the control group(group C ,n=20) .Patients in group B were given rosuvastatin(crestor produced by astrazeneca company) 5~10mg within 24~28h after the diagnosis of ACS once per night based on routine treatment .The course was 8 weeks .Double antibody sandwich enzyme‐linked im‐munosorbent assay(ELISA) was used to detect serum IL‐6 of patients in two groups before and after treatment ,and im‐muno‐turbidimetry was used to determine hs‐CRP .[Results]Compared with group C ,blood lipids ,IL‐6 and hs‐CRP in ACS patients before treatment increased significantly( P<0 .01) ,but there was no significant difference between group A and group B( P>0 .05) .Low density lipoprotein cholesterol(LDL‐C) ,IL‐6 and hs‐CRP in group B after treatment de‐creased significantly( P<0 .05) ,and there was significant different between group B and group A( P<0 .05) .[Conclu‐sion]ACS patients have inflammatory response .Early use of rosuvastatin can improve inflammatory status and reduce car‐diovascular events of patients .
引用本文:
丁慧敏. 急性冠脉综合征患者早期应用瑞舒伐他汀对血脂及血清炎症介质的影响[J]. 医学临床研究, 2015, 32(1): 119-121.
DING Hui-min. Influence of Early Use of Rosuvastatin on Blood Lipids and Inflammatory Factors in Patients with Acute Coronary Syndrome. JOURNAL OF CLINICAL RESEARCH, 2015, 32(1): 119-121.
2015, Vol. 32 
